Last reviewed · How we verify
Carboplatin plus Paclitaxel
Carboplatin and paclitaxel work together as a chemotherapy combination: carboplatin creates DNA crosslinks to kill cancer cells, while paclitaxel stabilizes microtubules to prevent cell division.
Carboplatin and paclitaxel work together as a chemotherapy combination: carboplatin creates DNA crosslinks to kill cancer cells, while paclitaxel stabilizes microtubules to prevent cell division. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.
At a glance
| Generic name | Carboplatin plus Paclitaxel |
|---|---|
| Sponsor | The University of Hong Kong |
| Drug class | Chemotherapy combination (platinum agent + taxane) |
| Target | DNA (carboplatin); beta-tubulin (paclitaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin is a platinum-based alkylating agent that binds to DNA and forms interstrand crosslinks, preventing DNA replication and transcription in cancer cells. Paclitaxel is a taxane that binds to beta-tubulin and stabilizes microtubules, disrupting the mitotic spindle and blocking cell cycle progression. Together, they provide synergistic cytotoxic activity against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Breast cancer
- Other solid tumors (phase 3 dependent on specific trial)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Neuropathy (peripheral)
- Nausea/vomiting
- Alopecia
- Fatigue
- Hypersensitivity reactions
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin plus Paclitaxel CI brief — competitive landscape report
- Carboplatin plus Paclitaxel updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI